Rapid clozapine titration in treatment-refractory bipolar disorder

Journal of Affective Disorders

Volumn 166, Issue , 2014, Pages 168-172

  Ifteni, Petru ^a   Correll, Christoph U ^b,c,d   Nielsen, Jimmi ^e,f   Burtea, Victoria ^a   Kane, John M ^b,c,d   Manu, Peter ^b,c,d  

^a TRANSILVANIA UNIVERSITY OF BRASOV   (Romania)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

^f AALBORG UNIVERSITY   (Denmark)

Author keywords

Bipolar disorder; Clozapine; Discharge; Rapid titration; Symptom control; Tolerability

Indexed keywords

CLOZAPINE; VALPROIC ACID; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BIPOLAR DISORDER; BODY MASS; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MENTAL HOSPITAL; MONOTHERAPY; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; SMOKING; TITRIMETRY; DAY CARE; DRUG ADMINISTRATION; LENGTH OF STAY; MEDICAL RECORD; MIDDLE AGED; PSYCHOLOGY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CLOZAPINE; COHORT STUDIES; DAY CARE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HOSPITALIZATION; HOSPITALS, PSYCHIATRIC; HUMANS; LENGTH OF STAY; MALE; MEDICAL RECORDS; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84901984095     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2014.04.020     Document Type: Article

References (24)

1. B. Barbini, P. Scherillo, F. Benedetti, G. Crespi, C. Colombo, and E. Smeraldi Response to clozapine in acute mania is more rapid than that of chlorpromazine Int. Clin. Psychopharmacol. 12 1997 109 112 (Pubitemid 27286560)
2. L. Bryant-Comstock, M. Stender, and G. Devercelli Health care utilization and costs among privately insured patients with bipolar disorder Bipolar Disord. 4 2002 398 406
3. J.R. Calabrese, S.E. Kimmel, M.J. Woyshville, D.J. Rapport, C.J. Faust, P.A. Thompson, and H.Y. Meltzer Clozapine for treatment-refractory mania Am. J. Psychiatry 153 1996 759 764 (Pubitemid 26170535)
4. J.S. Chang, K.S. Ha, K. Young Lee, Y. Sik Kim, and Y. Min Ahn The effects of long-term clozapine add-on therapy on the rehospitalization rate and the mood polarity patterns in bipolar disorders J. Clin. Psychiatry 67 2006 461 467
5. S.B. Dusetzina, J.F. Farley, M. Weinberger, B.N. Gaynes, B. Sleath, and R.A. Hansen Treatment use and costs among privately insured youths with diagnoses of bipolar disorder Psychiatr. Serv. 63 2012 1019 1025
6. M. Eckman, O. Granstrom, S. Omerov, J. Jacob, and M. Landen The societal cost of bipolar disorder in Sweden Soc. Psychiatry Psychiatr. Epidemiol. 48 2013 1601 1610
7. B.S. Fehr, M.E. Ozcan, and T. Suppes Low doses of clozapine may stabilize treatment-resistant bipolar patients Eur. Arch. Psychiatry Clin. Neurosci. 255 2005 10 14 (Pubitemid 40558100)
8. H. Grunze, E. Vieta, G.M. Goodwin, C. Bowden, R.W. Licht, H.J. Moller, and S. Kasper The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder World J. Biol. Psychiatry 14 2013 154 219
9. Guy, W., 1976. ECDEU Assessment Manual for Psychopharmacology - Revised (DHEW Publ No ADM 76-338). Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs.
10. P. Ifteni, J. Nielsen, V. Burtea, C.U. Correll, J.M. Kane, and P. Manu Effectiviness and safety of rapid clozapine titration in schizophrenia Acta Psychiatr. Scand. 2013 20 (epub ahead of print)
11. J. Kane, G. Honigfeld, J. Singer, and H. Meltzer Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine Arch. Gen. Psychiatry 45 1988 789 796
12. D.L. Kelly, R.R. Conley, S. Feldman, Y. Yu, R.P. McMahon, and C.M. Richardson Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia Psychiatr. Q. 77 2006 81 95 (Pubitemid 43060798)
13. K.C. Lee, P.R. Finley, and B.K. Alldredge Risk of seizures associated with psychotropic medications: emphasis on new drugs and new findings Expert Opin. Drug Saf. 2 2003 233 247
14. P. Manu, D. Sarpal, O. Muir, J.M. Kane, and C.U. Correll When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature Scizophr. Res. 134 2012 180 186
15. S.L. McElroy, E.C. Dessain, H.G. Pope Jr., J.O. Cole, P.E. Keck Jr., A.R. Frankenberg, H.G. Aizley, and S. O'Brien Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia J. Clin. Psychiatry 52 1991 411 414
16. J. Nielsen, C.U. Correll, P. Manu, and J.M. Kane Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J. Clin. Psychiatry 74 2013 603 613
17. J. Nielsen, J.M. Kane, and C.U. Correll Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study Bipolar Disord. 14 2012 863 869
18. L.K. Oyewumi, Z.Z. Cernovsky, and D.J. Freeman Autonomic signs and dosing during the initial stages of clozapine therapy Med. Sci. Monit. 10 2004 19 23
19. R. Roge, B.K. Moller, C.R. Andersen, C.U. Correll, and J. Nielsen Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far? Schizophr. Res. 140 2012 204 213
20. K.J. Ronaldson, P.B. Fitzgerald, A.J. Taylor, D.J. Topliss, R. Wolfe, and J.J. McNeil Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study Schizophr. Res. 141 2012 173 178
21. A. Safferman, J.A. Lieberman, J.M. Kane, S. Szymanski, and B. Kinon Update on the clinical efficacy and side effects of clozapine Schizophr. Bull. 17 1991 247 261
22. M. Stensland, P.R. Watson, and K.L. Grazier An examination of costs, charges, and payments for inpatient psychiatric treatment in community hospitals Psychiatr. Serv. 63 2012 666 671
23. T. Suppes, S.L. McElroy, J. Gilbert, E.C. Dessain, and J.O. Cole Clozapine in the treatment of dysphoric mania Biol Psychiatry 32 1992 270 280
24. C.A. Zarate Jr., M. Tohen, M.D. Banoy, M.K. Weiss, and J.O. Cole Is clozapine a mood stabilizer? J. Clin. Psychiatry 56 1995 108 112